Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

oncNGS

Financiado

Cerrado

NGS diagnostics in 21st century oncology the best for all at all times

oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecula... ver más

30/04/2026

Sciensano

12M€

Presupuesto del proyecto: 12M€

Líder del proyecto

SCIENSANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-13

SC1-BHC-10-2019: Innovation Procurement: Next genera... Specific Challenge:We observe a progressive shift in routine diagnostics, and more particularly in p...

I+D

Cerrada hace 6 años

0% 90% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

Sciensano

8.44M€ | Lider

IFO

N.D. | Participante

FUNDACION INSTITUTO ESTUDIOS...

48.30K€ | Participante

INSTITUT CURIE FONDATION

300.11K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 76 meses Fecha Inicio: 2019-12-13
Fecha Fin: 2026-04-30

Líder del proyecto

SCIENSANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 12M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting. Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests. oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis) oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores